Catheter Precision (VTAK) AI Stock Analysis

• Market Cap: $3.38M
• Dividend Yield: N/A
• Average Volume (3M): 309.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: 82.96%
• EPS Growth: 82.04%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 1,487,266
• 10 Day Avg. Volume: 759,143
• 30 Day Avg. Volume: 309,336
• PEG Ratio: 0.03
• Price to Book (P/B): 2.38
• Price to Sales (P/S): 66.59
• P/FCF Ratio: -3.00
• Enterprise Value/Market Cap: 4.60
• Enterprise Value/Revenue: 21.26
• Enterprise Value/Gross Profit: 104.84
• Enterprise Value/Ebitda: -1.14
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $2.00 ▼(-2.44% Downside)

VTAK's overall stock score is primarily impacted by its poor financial performance and valuation. The company's ongoing losses and negative cash flows are significant concerns. Technical analysis suggests bearish momentum, although oversold conditions could offer a potential rebound opportunity. The lack of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Product Adoption

The rapid adoption of the LockeT closure device in South Africa indicates strong product acceptance and potential for market expansion, enhancing long-term revenue growth.

International Expansion

Expanding installations in France underlines international growth, strengthening Catheter Precision's global presence and long-term market position.

Innovation and Patents

New patents enhance competitive advantage by protecting innovations, supporting sustained market leadership and product differentiation.

Negative Factors

Declining Revenue

Persistent revenue decline indicates challenges in market demand or competitive positioning, impacting long-term financial health and growth potential.

Operational Losses

Negative margins reflect ongoing operational inefficiencies, posing risks to profitability and requiring strategic improvements for sustainable growth.

Cash Flow Challenges

Negative cash flow highlights liquidity risks and limits investment capacity, necessitating improved cash management for financial stability.

Catheter Precision Business Overview & Revenue Model

Company Description

Catheter Precision (VTAK) is a medical technology company that specializes in advanced cardiac mapping solutions. The company focuses on developing innovative tools and software to enhance the precision of catheter-based procedures, particularly in the treatment of arrhythmias. Their core products include the FDA-cleared Cardiac Mapping System, which aids physicians in locating and treating abnormal heart rhythms with greater accuracy and efficiency, ultimately improving patient outcomes in electrophysiology.

How the Company Makes Money

Catheter Precision generates revenue primarily through the sale of its cardiac mapping systems and related software solutions to hospitals and healthcare providers. The company also earns income from ongoing sales of consumable products associated with its systems, including catheters and accessories used during procedures. Additionally, Catheter Precision may benefit from service contracts and maintenance agreements for their equipment, providing a recurring revenue stream. Strategic partnerships with hospitals and medical institutions, as well as collaborations with research organizations, may further enhance their market reach and contribute to their overall earnings.

Catheter Precision Financial Statement Overview

Summary

The financial performance is weak, with declining revenues and persistent operational losses. The balance sheet shows moderate leverage but negative return on equity, and cash flow challenges are evident with ongoing negative free cash flow.

Income Statement

The income statement reveals a significant decline in revenue from 2019 to 2024, with a negative revenue growth rate. Gross profit margin is positive, but both EBIT and net income margins are negative, indicating persistent operational losses. This suggests challenges in achieving profitability despite efforts to control costs.

Balance Sheet

The balance sheet highlights a moderately leveraged position with a debt-to-equity ratio that is manageable. However, the return on equity is negative due to continuing net losses, which is a concern for investor returns. The equity ratio shows a reasonable proportion of equity financing, suggesting some financial stability.

Cash Flow

Cash flow analysis shows ongoing negative free cash flow, indicating cash outflows that exceed inflows from operations. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. The company needs to improve operational efficiency to enhance cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	730.00K	420.00K	442.00K	14.00K	22.00K	259.00K
Gross Profit	148.00K	378.00K	412.00K	-147.00K	-1.54M	-1.91M
EBITDA	-13.56M	-11.30M	-15.11M	-22.37M	-25.85M	-33.04M
Net Income	-17.38M	-16.64M	-70.57M	-26.86M	-25.07M	-36.05M
Balance Sheet
Total Assets	25.47M	27.77M	30.74M	16.84M	21.04M	33.44M
Cash, Cash Equivalents and Short-Term Investments	1.07M	2.87M	3.56M	15.86M	15.04M	23.91M
Total Debt	3.48M	1.79M	372.00K	0.00	2.26M	4.88M
Total Liabilities	19.02M	16.01M	9.54M	7.58M	7.37M	12.29M
Stockholders Equity	6.78M	11.76M	21.19M	9.26M	13.67M	21.15M
Cash Flow
Free Cash Flow	-9.66M	-9.34M	-20.70M	-22.59M	-27.89M	-28.37M
Operating Cash Flow	-9.64M	-9.27M	-20.62M	-22.57M	-27.63M	-28.30M
Investing Cash Flow	-51.00K	-67.00K	-61.00K	21.00K	3.80M	15.93M
Financing Cash Flow	9.50M	8.65M	8.39M	23.36M	14.96M	21.69M

Catheter Precision Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Neutral. The current price of 2.05 is above the 20-day moving average (MA) of 2.02, below the 50-day MA of 2.35, and below the 200-day MA of 4.28, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 48.93 is Neutral, neither overbought nor oversold. The STOCH value of 85.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VTAK.

Catheter Precision Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PAVM	48 Neutral	$10.04M	0.32	20.03%	―	-99.28%	-46.16%
NUWE	43 Neutral	$2.43M	-0.08	-467.14%	―	-8.93%	97.80%
VTAK	41 Neutral	$3.38M	-0.03	-173.74%	―	82.96%	82.04%
VERO	40 Underperform	$3.92M	-0.04	-854.61%	―	-12.39%	44.61%
HSCS	39 Underperform	$6.49M	―	-193.24%	―	-66.40%	65.99%
AEMD	38 Underperform	$3.44M	-0.07	-191.39%	―	―	76.53%

Catheter Precision Corporate Events

Catheter Precision Increases Authorized Shares to 500 Million

On October 10, 2025, Catheter Precision held a Special Meeting of stockholders where approximately 43.1% of the outstanding shares of common stock were represented. During the meeting, stockholders approved three proposals: an increase in authorized shares from 60 million to 500 million, the ratification of WithumSmith+Brown, PC as the independent accounting firm for 2026, and the potential adjournment or postponement of the meeting to solicit more votes if necessary.

The most recent analyst rating on (VTAK) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.